Flavonoids and chalcones are known for their manifold biological activities, of which many affect the central nervous system. Pyranochalcones were recently shown to have a great neurogenic potential, which is partly due to a specific structural motif-the pyran ring. Accordingly, we questioned if other flavonoid backbones with a pyran ring as structural moiety would also show neurogenic potential. Different semi-synthetic approaches starting with the prenylated chalcone xanthohumol, isolated from hops, led to pyranoflavanoids with different backbones. We identified the chalcone backbone as the most active backbone with pyran ring using a reporter gene assay based on the promoter activity of doublecortin, an early neuronal marker. Pyranochalcones therefore appear to be promising compounds for further development as a treatment strategy for neurodegenerative diseases.
The prenylated chalcone xanthohumol C from Humulus lupulus L. -hops- was identified as an inducer of neuronal lineage-specific differentiation of neuronal stem cells [1]. Furthermore, a structure-activity study revealed that a pyrano ring is a structural characteristic responsible for the neuro-differentiation effect and that the unknown targets respond to structural changes [2]. Since the induction of neuronal-differentiation is the key mechanism concerning a therapy for neurodegenerative diseases using the body’s own regeneration mechanism, xanthohumol C, is a promising candidate for further pharmaceutical evaluation. To evaluate the potential of xanthohumol C as a drug candidate, studies concerning absorption, distribution and metabolism are needed. Recently, a formulation of xanthohumol C in cyclodextrin was characterized and enhanced water solubility was determined. Furthermore, a small animal study showed that the compound is absorbed in this formulation and reaches the brain as target [3]. To the best of our knowledge, there is only little known about biotransformation of this promising candidate. Accordingly, human microsomes were used to metabolize xanthohumol C and HPLC/MS analysis showed that xanthohumol C was transformed into four main metabolites by cytochrome monooxygenases p450 (CYPs). Using mostly selective inhibitors and a synthesized isotope labelled internal standard, the CYPs 2C8, 2C19 and 2D6 were identified as possible main metabolizers.